ZFHX3 and non-small cell lung carcinoma: Recently, studies have suggested that NSCLC patients with ZFHX3 mutation had a good prognosis after immunotherapy, and their PFS and OS were significantly longer than those of ZFHX3 wild-type patients, especially the ZFHX3 mutated LUAD patients (Zhang et al. 2021b, a).